Fee-for-service agreement calls for inhibitor discovery for two related targets.



Argenta Discovery entered into a fee-for-service collaboration with CellCentric. Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise to discover inhibitors for two potential epigenetic-related therapeutic targets.


“Their decision to work with us is based on our contract drug discovery team’s acknowledged expertise in hit identification and assay development,” notes Christopher Ashton, Argenta’s chief executive.


Will West, CEO of CellCentric adds that Argenta’s know-how in hit identification, assay development, and screening will help advance the company’s knowledge and expertise in epigenetic research.








This site uses Akismet to reduce spam. Learn how your comment data is processed.